Medivation Announces Presentation of Phase I Talazoparib Combination Data in Several Advanced Cancers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Medivation (MDVN) Preclinical Excitement Seems To Be Bearing Fruit - Stifel
April 18, 2016 9:59 AM EDTStifel analyst, Thomas Shrader, thinks that preclinical excitement for Medivation's (NASDAQ: MDVN) talazoparib is bearing fruit. Much of Medivations excitement in Talazoparib is based on the drugs ability to trap the PARP enzyme on the DNA and act like a Topo II inhibitor in addition to inhibiting PARP enzymatic activity. Topo II inhibitors from the anthracycline family are the most broadly active drugs... More
